1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Convalescent Plasma Therapy Global Market Report 2021: COVID-19 Implications And Growth To 2030

Convalescent Plasma Therapy Global Market Report 2021: COVID-19 Implications And Growth To 2030

  • September 2021
  • 175 pages
  • ID: 6151638
  • Format: PDF
  • The Business Research Company


Table of Contents

Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited, and Orthosera Kft.

The global convalescent plasma therapy market is expected to grow from $0.026 billion in 2020 to $0.028 billion in 2021 at a compound annual growth rate (CAGR) of 7.7%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $0.05 billion in 2025 at a CAGR of 16%.

The convalescent plasma therapy market consists of sales of convalescent plasma obtained from patients who have recovered from an infection.Convalescent plasma is the plasma collected from the recovered or convalesced people consisting of the antibodies against the infection causing microorganism.

The revenue generated by the market includes the sales of convalescent plasma collected from people post-infection, which will be utilized for prophylaxis and treatment of infected patients with the respective microorganism. The companies engaged in the convalescent plasma market are primarily engaged in the collection and processing of convalesced plasma for the utilization by research institutes, laboratories, hospitals and clinics.

The convalescent plasma therapy market covered in this report is segmented by application into prophylaxis, treatment. It is also segmented by end-users into hospitals & clinics, laboratories & research institutes and by antibody type into IgM, IgG, IgA.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The availability of scant evidence regarding the safety and efficacy of convalescent plasma therapy led to strict guidelines by government authorities.Different government authorities like the US FDA, CDSCO of India and others have approved COVID-19 convalescent plasma for investigational use only and not for prescribed indication.

In May 2020, FDA released guidelines for COVID-19 convalescent plasma therapy, which stated that the administration of COVID-19 convalescent plasma must be under the investigational new drug application (IND) for clinical trials, expanded access and single-patient emergency only.Even for a single patient emergency, an eIND must be filed with FDA for the use of convalescent plasma therapy, provided, the health care provider must determine that the probable risk from the investigational drug is not greater than the probable risk from the disease or condition.

COVID-19 convalescent plasma should be obtained from an FDA-registered blood establishment that follows the donor eligibility criteria and donor qualifications.The manufacturing process and shelf life should be the same as that of other similar plasma products.

These strict guidelines framed by authorities are expected to limit the market growth.

In March 2020, Grifols, a Spain-based multinational pharmaceutical and chemical manufacturer that develops, produces, and markets innovative solutions under divisions - Bioscience, Diagnostic, Hospital and Bio Supplies, announced its collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies.Under this collaboration, Grifols will collect plasma from FDA approved plasma collection centers to develop a hyperimmune globulin as a treatment option for COVID-19 patients and will support the convalescent plasma therapy approach by providing inactivated plasma for transfusion using viral inactivation technology (methylene blue).

FDA is a federal agency and BARDA is an authority of the United States Department of Health and Human Services that protects public health through the transition of medical products like vaccines, biopharmaceuticals, pharmaceuticals, and others from research to FDA approval for the public use.

Higher efficacy and safety evaluated during the trials conducted for CPT in COVID-19 patients can drive the market growth during the forecast period.Convalescent plasma transfusion has been of interest in the historical period for the treatment of other infectious disease outbreaks such as SARS?1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1.

In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate.In May 2020, a study published in the Journal of Medical Virology stated that with convalescent plasma therapy, the mortality rate may be reduced in critically ill patients, beneficial effects on clinical symptoms will be observed, and an increase in neutralizing antibody titers and disappearance of SARS?CoV?2 RNA will be observed.

The safety and efficacy of the convalescent plasma therapy in COVID-19 patients will boost market growth.

The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market.Convalescent plasma therapy utilizes the antibodies produced against coronavirus by the donor to improve the immunity of the recipient.

Companies are initiating trials, collaborating and investing for antibody-based COVID-19 therapy.In April 2020, GSK entered into a collaboration with Vir Biotechnology and invested $250 million in Vir to support the development of anti-viral antibody-based solutions against novel coronavirus.

In April 2020, Biomedical Advanced Research Development Authority (BARDA) partnered with Emergent BioSolutions to fund $14.5 million to support the development of human plasma-derived therapy which is COVID-Human Immune Globulin (COVID-HIG) for treating COVID-19 in severe hospitalized and high-risk patients. In April 2020, global plasma companies like CSL Behring, Takeda Pharmaceutical Company Limited, Biotest, BPL, LFB, and Octapharma collaborated to develop plasma-derived COVID-19 Hyperimmune Therapy. As convalescent plasma therapy utilizes antibodies, the focus over antibody-based COVID-19 therapy is expected to boost the market growth.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Bioanalytical Testing Services Market Research Report by Type, by Application, by End User, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • November 2021
  • 188 pages

Bioanalytical Testing Services Market Research Report by Type (Biomarker Testing, Cell-Based Assays, and Method Development Optimization & Validation), by Application (Cardiology, Gastroenterology, and ...

  • United States
  • Infectious Disease
  • Biopharmaceutical
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on